Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

NCT05313243 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

T-Cell Lymphoma

Interventions

DRUG: Brentuximab vedotin
DRUG: Pembrolizumab

Sponsor

Yale University

Collaborators

[object Object]